News
Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.
Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors
Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
Marc Robillard will present the progress of Tagworks click-cleavable radiotherapeutics program at the 6th Targeted Radiopharmaceuticals Summit in Amsterdam on December 5, 2024.
We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.
Madeira, September 4-6, 2024; www.antibodyseries.com
Boston, September 9-10, 2024; www.adc-partnering.com
Boston, August 20-22, 2024; www.adc-linker-conjugation.com
We are pleased to announce the appointment of Bianca Matthee as our VP of Research Operations.
Marc Robillard will present Tagworks at the 24th BioEquity Europe on May 14 at 11:30 in San Sebastián, Spain.
Curious about what we do? Get in touch!
Contact
T +31 85 800 8550
info@tagworkspharma.com
Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED Nijmegen
The Netherlands
Stay updated
© Tagworks Pharmaceuticals, 2025 | Terms of use | Design by Ape to Zebra